Table 1 Baseline demographic and clinical characteristics of the study cohort

Age (years): median (Q1–Q3)

346

63

(51–72)

Disease duration (years): median (Q1–Q3)

346

10

(7–17)

BMI (kg/m²): median (Q1–Q3)

310

23.4

(21–27)

Male sex: N (%)

346

60

(17.3)

Diffuse cutaneous subset: n (%)

283

65

(23)

Raynaud’s phenomenon: n (%)

342

327

(95.6)

Digital ulcers ever: n (%)

335

114

(34.0)

mRSS: median (Q1–Q3)

337

3

(0–8)

Joint synovitis: n (%)

344

61

(17.7)

Joint contractures: n (%)

340

99

(29.1)

Esophageal symptoms (reflux, dysphagia): n (%)

344

185

(53.8)

Stomach symptoms (early satiety, vomiting): n (%)

341

102

(29.9)

Intestinal symptoms (diarrhea, bloating, constipation): n (%)

344

124

(36)

Malabsorption syndrome: n (%)

306

7

(2.3)

Intestinal pseudo-obstruction: n (%)

311

4

(1.3)

Barrett’s esophagus

343

9

(2.6)

Pulmonary hypertension: n (%)

331

35

(10.6)

Thorax HRCT: lung fibrosis: n (%)

328

135

(41.2)

FVC: median (Q1–Q3)

339

97

(84–110)

Renal crisis: n (%)

343

6

(1.7)

ANA positive: n (%)

345

340

(98.6)

Anti-centromere positive: n (%)

327

155

(47.4)

Anti-topoisomerase I positive: n (%)

332

84

(25.3)

Anti-RNA polymerase III positive: n (%)

310

36

(11.6)

CRP (mg/dl): median (Q1–Q3)

312

1.6

(0.7–4)

ESR (mm/h): median (Q1–Q3)

329

12

(6–23.5)

Hb (g/dl): median (Q1–Q3)

310

13.2

(12.4–14.1)